Pharmafile Logo
Pharmafocus logo
Advanced Search

Cancer Drugs Fund

Showing 15 posts of 53 posts found.

Pfizer’s Ibrance combo authorised via the Cancer Drugs Fund for advanced breast cancer

January 15, 2020
Research and Development Cancer Drugs Fund, NICE, Pfizer, ibrance, pharma

NICE, the drug watchdog for England and Wales, has given its approval for Pfizer’s Ibrance (palbociclib) in combination with AstraZeneca’s …

News
pfizer_building_logo1_19

Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund

November 28, 2019
Manufacturing and Production, Research and Development Cancer Drugs Fund, NHS, NICE, Pfizer, breast cancer, ibrance, pharma

Today it was announced that the National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) to …

News
images

NICE rejects Keytruda for routine use in NHS bladder cancer treatment

November 27, 2019
Research and Development Cancer Drugs Fund, bladder cancer, cancer research

The National Institute for Health and Care Excellence (NICE) has given an initial ‘no’ for Keytruda’s (pembrolizumab) use in treating …

News

AstraZeneca’s Lynparza approved via Cancer Drugs Fund for BRCA+ gynaecological cancers

July 26, 2019
Medical Communications, Sales and Marketing AstraZeneca, Cancer, Cancer Drugs Fund, NHS, NICE, UK, lynparza, pharma

NICE has published final guidance which approves AstraZeneca’s Lynparza (olaparib) for use on the NHS as a maintenance therapy for …

News

BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund

April 5, 2019
Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, Kidney cancer, NICE, UK, Yervoy, opdivo

NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to …

News
opdivo_1_1

Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund

November 30, 2018
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, NICE, UK, melanoma, pharma

Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer …

News

Cancer Drugs Fund to offer MSD’s Keytruda for lung cancer

November 22, 2018
Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NICE, UK, keytruda, pharma

MSD’s Keytruda (pembrolizumab) will now be made available via the Cancer Drugs Fund for patients in England, as NICE announces …

News

Kymriah to be made available in UK for paediatric leukaemia patients via Cancer Drugs Fund

November 15, 2018
Sales and Marketing CAR-T, Cancer, Cancer Drugs Fund, Kymriah, NHS, NICE, leukaemia, pharma

NICE has announced its recommendation that Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) be made available in the treatment of relapsed …

News
humacao_exterior

BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer

October 13, 2017
Sales and Marketing BMS, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, NICE, opdivo, pharma, pharmaceutical

Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for …

News

NICE gives final draft guidance on two key cancer drugs

October 12, 2017
Sales and Marketing Bayer, CDF, Cancer, Cancer Drugs Fund, Erivedge, NICE, Roche, Stivarga

NICE has announced it has published its final draft guidance for two cancer treatments, covering Bayer’s Stivarga (regorafenib) in the …

News
shutterstock_235920349

NICE and the CDF: Are they still up to scratch?

October 4, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE

Originally published in the October issue of Pharmafocus, Matt Fellows explores medical and pharmaceutical opinion of the divisive institute to …

Feature
pharmafocus_sept_2016_cover

The September issue of Pharmafocus is now live!

August 31, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myer's Squibb, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, Cloud Computing, Pharmafocus, Pharmafocus new issue, brexit, clinical trial transparaency, opdivo

The latest edition of Pharmafocus is available online now. In this issue, we explore the future of the clinical trial …

News

NICE says Afinitor and Imbruvica “may be removed” from Cancer Drugs Fund

August 18, 2016
Research and Development, Sales and Marketing Afinitor, Cancer Drugs Fund, Janssen, NICE, Novartis, imbruvica

NICE has published draft guidance advising the removal of Novartis’s Afinitor (everolimus) and Janssen’s Imbruvica (ibrutinib) from the Cancer Drugs …

News
takeda_tokyo_hq

Old CDF drug not recommended in initial NICE guidance due to lack of evidence

August 10, 2016
Research and Development, Sales and Marketing Adcetris, Cancer Drugs Fund, NICE, Takeda, hodgkin's lymphoma

The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Takeda’s Adectris (brentuximab vedotin), despite …

News
roche_close

Roche urges reform of Cancer Drugs Fund as NICE takes control

July 29, 2016
Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE, Roche

Roche has warned that cancer patients in England are facing into an “uncertain future” as the new Cancer Drugs Fund …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024